content top

Young EVRS Course: Treatment of DME

                    Exerts: Didier Ducournau & Paul Tornambe Young EVRS Course is dedicated to ophthalmologist at the beginning of their carriers. The course is intended to serve as the forum for asking questions and getting valuable answers. World class experts Didier Ducournau and Paul Tornambe will be gathered to present the topics. So prepare your questions and grill the...

Read More

Retinal Inflammation and DME: Novel Approach

Media not available due to technical recording problems. EVRS is very sorry for the inconvenience.   Objectives: To evaluate the efficacy of topical nepafenac in patients with impaired blood-retinal barrier (BRB) in the macular area. Methods: In a prospective pilot study 15 eyes were included; in the first visit and controls complete eye examination was performed (mean follow-up: 79 days). Visual acuity (VA), central thickness (CT) and...

Read More

577nm Yellow Laser vs 532nm Green Laser for DME

Media not available due to technical recording problems. EVRS is very sorry for the inconvenience.   Advantages: Macular photocoagulation is a standard of care therapy for Diabetic macular edema and it is desirable to use a laser wavelength that is least noxious to the macular tissue. We present our study and concept, suggesting that Yellow laser (577 nm) be used a safe and efficacious alternative to the standard Green Laser (532nm) as...

Read More

Subthreshold Diode Micropulse Photocoagulation for Significant DME

Media not available due to technical recording problems. EVRS is very sorry for the inconvenience.   Purpose: To assess effect of micropulse diode laser (MPDL) on best corrected visual acuity (BCVA) and central foveal thickness (CFT) in treatment of clinically significant diabetic macular oedema (CSME) as compared to conventional argon green laser (CGL) treatment. Design: Single-center, prospective, interventional, comparative...

Read More

Change of Microaneurysm in Diabetic Retinopathy Patients Who Undergo Bevacizumab Injection

Purpose: To evaluation of microvasular change(microaneurysm) in diabetic retinopathy patients who undergo intravitreal bevacizumab injection by FAG(fluorescein angiography). Method: Thirty- one eyes of 31 diabetic retinopathy patients undergoing intravitreal bevacizumab injection(1.25mg/0.05ml) only one eye were included in this study. The control group(31 eyes) were the opposite eyes. We made an exception for both intravitreal bevacizumab...

Read More

Vitrectomy in Diabetic Macular Edema

For many years, pars plana vitrectomy with posterior hyaloid detachment and peeling of internal limiting membrane (ILM) has been considered a treatment option for diabetic macular edema by retina surgeons worldwide. The 2012 large scale study by EVRS surgeons showed that the surgical option alone resulted, by far, in the most significant visual acuity improvement. However the surgical treatment has, so far, failed to gain widespread...

Read More

My Way of Treating Diabetic ME

Diabetic macular edema is a multifactorial disorder that needs a multimodal and individualized approach. First we must understand the main mechanism behind each particular case (ischemic, inflammatory, tractional or even mixed) and then select the best treatment option. If it is not possible to clarify the main mechanism (which can change with time, as the natural history of this ocular disease) we should always choose the best way that...

Read More

ILM Peeling During Vitrectomy for Tractional DME. My Way

I do ERM-ILM peeling by using: Chandelier illumination, aspheric macular contact lens, 23 G needle OR closed tip ILM Forceps for creating the ILM flap, clamping the infusion cannula during the BBG stain injection. Chandelier allows for satisfactory illumination with a free second hand that stabilizes the working hand and thus provides stability, precision, control and dexterity. However, positioning and redirecting by the assistant may...

Read More

Removal of the Internal Borderline Membrane in DME Treatment

buy zyban nline canada. buy zyban nline uk. buy cheap zyban nline. rder zyban n prescriptin. nn-prescriptin zyban. zyban nline n prescriptin. zyban generic … Poster Olga Yevsyukova apr 4, 2012 – most of the dramatic side effects occur rarely, buy zoloft from mexico, zoloft online cod , zoloft maximum dosage, three weeks apart. price advair diskus generic name of advair diskus order fluticasone Topicality of the...

Read More

MH After Intravitreal Ranibizumab Injection for DME

Poster Jaeryung Oh Purpose: To report a case of macular hole formed after intravitreal ranibizumab injection in diabetic macular edema. Case summary: A 76-year-old woman with a 30-year history of type 2 diabetes visited the clinic presenting with the complaint of decreased vision in her right eye. The best-corrected visual acuity of the right eye was 6/20, and 6/12 in the left eye. Intraocular pressure was 20 mmHg in her right eye and she...

Read More

Macular Photocoagulation Assisted by Intravitreal Bevacizumab (IVB) Versus Triamcinolone (IVTA) in Diabetic Macular Edema with Serous Macular Detachment

Advantage: Diabetic macular edema (DME) with serous macular detachment (SMD) responds poorly to laser treatment due to presence of subretinal fluid but has been seen to resolve following both IVB and IVTA. Re-injections maybe required owing to their limited period of action. We, thus, compared the efficacy of IVTA and IVB followed by laser photocoagulation, in treating DME with SMD. Methods: In this prospective interventional case...

Read More

The EVRS Macular Edema Study Results

Read More

The Effectiveness and Safety of Triamcinolone Injections in DME

Advantages: Intravitreal triamcinolone injections turned out to be effective in reducing macular edema and improving vision in refractory DME after a laser treatment or even as an initial treatment. The steroid-related adverse events, e.g. cataract and elevated intraocular pressure, should be weighed against the benefits of the treatment. Methods: Twenty-mg triamcinolone acetonide intravitreal injections (IVTA) were applied to 110 DME...

Read More

Effectivity of Intravitreal Triamcinolone Injections for Diabetic Cystoid Macular Edema

Persistent diffuse macular edema (ME) or cystoid ME is a result of chronic inflammation with the generalized breakdown of the inner blood retinal barrier and fluid accumulation, primarily in the outer plexiform layer. This process is characterized by the development of hard exudates and progressively lost of vision. Triamcinolone acetonide is the most effective anti-inflammatory agent. After injection into the vitreous cavity...

Read More

Comparison of Endovitreal Triamcinolone with Betamethasone in DME

Advantages: Use of intravitreal injection of crystalline corticosteroids- bethamethasone and triamcinole dose of 4 mg in 0.1 ml allows to improve visual acuity and restore adequate morphological retinal thickness in patients with diffuse diabetic macular edema. Methods: Comparison of efficacy and safety of intravitreal injection of 4 mg (0.1 mL) triamcinolon (36 patients – 40 eyes) and 4 mg (0.1 mL) bethamethasone (60 patients...

Read More

Fluocinolone Acetonide Implants for the Treatment of Chronic DME

Advantages: Given the chronic nature of diabetic macular edema (DME), an implant (ILUVIEN®) that releases a continuous, submicrogram daily dose of fluocinolone acetonide (FAc) could fill an unmet need for continuous long-term therapy. Methods: The Fluocinolone Acetonide in Diabetic Macular Edema (FAME) study consisted of 2 randomized, prospective, multicenter, double-masked, sham-controlled, parallel-group phase 3 trials enrolling...

Read More

Micropulse Contiguous Grid Laser for Resistant Diffuse DME

Purpose: To investigate micropulse contiguous grid laser (MCGL) for DDME involving the fovea, and to correlate OCT findings with resolution target visual fields (RTVF) scotomas and global macular acuity (GMA). Methods: One year retrospective review of sequentially treated eyes including, OCT, FA, RTVF and NEI-VFQ 25. Results: In 56 eyes GMA improved 0.2 logMAR in 34%, with none worsening >0.3 logMAR. Central OCT decreased 173 µm+9.3....

Read More

Effectiveness of Combined Betamethasone and Laser Coagulation for DME

Advantages: Combined treatment of diffuse diabetic macular edema using intravitreal injection of bethamethasone and laser coagulation is effective in improving visual acuity and restoration of the morphofunctional state of the retina. Methods: Intravitreal injection 4 mg (0.1 ml) of bethamethasone combined with laser coagulation was conducted in 33 patients (33 eyes) with diffused diabetic macular edema. Patients were divided into 2...

Read More

Micropulse Laser Following Intra Vitreal Bevacizumab in Diffuse DME

Advantages: Intravitreal bevacizumab followed by laser micropulse in CSME offers a clear advantage of non-inducing a visible retinal burn and having a potential efficiency in reducing foveal thickness and visual acuity Methods: Prospective case series. One hundred and twenty cases of non-ischemic non-tractional CSME with macular thickness more than 400 microns as defined by OCT were managed by initial intravitreal bevacizumab injection...

Read More

Micropulsed 577 nm Laser Stimulation for DME

Advantages: Laser stimulation seems to be effective, safer, non-tissue harmful and cost effective to treat diabetic macular edema. Methods: Eighty-eight eyes of 78 diabetic patients with DME were treated with yellow diode laser (577 nm) suited for micropulse treatment in macular area. ETDRS best corrected visual acuity, High definition optical coherence tomography to determine central macular thickness, Fluorescein angiography (FA) and...

Read More

Aflibercept (VEGF Trap Eye, Eylea) for Treatment of Diabetic Macular Edema

Advantages: Aflibercept (VEGF Trap Eye, Eylea) has a longer duration of action compared to ranibizumab (Lucentis). Methods: Randomized clinical trials. Effectiveness / Safety: In a phase II trial patients with diabetic macular edema gained 9.7 letters with aflibercept every 8 weeks and 13.1 letters with aflibercept every 4 weeks.  Phase III trials, VISTA and VIVID, are underway. Take home message: Aflibercept may be an effective...

Read More

Treatment of Diabetic Macular Edema with Ranibizumab

Advantages: Intravitreal ranibizumab improves vision of patients with diabetic macular edema. Methods: Review of recent clinical trials such as DRCR.net. Effectiveness / Safety: DRCR trials showed that in patients with diabetic macular edema, intravitreal ranibizumab with prompt or deferred focal/grid laser had superior Visual Acuity outcome compared with focal/grid laser treatment alone. Take home message: Intravitreal ranibizumab is...

Read More

ILM Peeling in Patients with Clinically Significant DME: Long-term Outcomes

Background: Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy. It is characterized to increased vascular permeability, due to blood-retinal barriers breakdown. Since macular laser treatment has shown poor efficacy to diffuse edema, surgical option of therapy is discussed. Several studies have proven the efficacy of pars plana vitrectomy (PPV) with inner limiting membrane (ILM) peeling in case of DME with a...

Read More

Does Vitreous Surgery for Diabetes Complications Have an Influence on the Course of Macular Edema in Long-term Follow-up?

Advantages: To evaluate the influence of vitreous surgery performed for vitreous hemorrhage and traction retinal detachment (macular edema excluded) as a complication of diabetic retinopathy with or without ILM peeling on macular edema formation. Additionally to evaluate long-term spectral domain optical coherence tomography (SD-OCT) follow- up of macular structure. Methods: 101 eyes of patients, who had undergone vitrectomy were...

Read More

PPV in Management of Type 1 Non-tractional DME After Failure of all Therapies

Advantages: PPV is a useful method in management of non-tractional, non-ischemic resistant diffuse diabetic macular edema associated with type 1 DM Methods: Type 1 Diabetic macular edema (DME) is typically managed by thermal laser, intravitreal injections and systemic control. An entity of diffuse DME persists despite all therapies. We present 5 cases of diffuse non-tractional, non-ischemic diffuse DME in type 1 DM managed by clear...

Read More

Vitrectomy Outcome in Resistent Non-tractional Diffuse DME

Advantages: Diabetic diffuse macular edema not responding to repeated IV injctions of Anti-VEGF and/or Triamcinolone may benefit from vitrectomy and ILM peeling. Vitrectomy helps to remove factors and mediators that may play a role in production of macular edema and/or its no or poor response to IV injections. ILM peeling ensure complete relieve of traction and may stimulate retinal glial cells mainly Muller cells to reactive fibrosis and...

Read More

Vitrectomy Outcome in Traction Diffuse DME

Advantages: In eyes with diffuse diabetic macular edema and OCT evidence of tangential and/or anteroposterior traction, Vitrectomy techniques allow complete release of traction, restoration of normal or near normal retinal architecture, and functional improvement. Methods: 65 eyes with traction diabetic diffuse macular edema underwent 23 gauge vitrectomy. All eyes underwent preoperative FA and OCT. Vitrectomy was combined with...

Read More

Vitrectomy for DME – An Alternative to Anti-VEGF Therapy?

Advantages: Vitrectomy for diabetic macula edema (DME) is and was used as a second line treatment. Published studies about this therapy option report mainly about small numbers of patients and show heterogenous results. In these times, when ranibizumab starts to dominate the therapy of DME, we want to present the functional results of vitrectomy for DME in a larger number of treated eyes. Methods: Retrospective analysis of the...

Read More

DME: 15 Injections or 1 Surgery?

Advantages: The first author has operated on over 600 eyes with DME in the last two decades. Surgery is typically a one-time intervention, unlike intraocular injections. Methods: Complete vitrectomy with detachment of the triamcinolone-marked posterior hyaloid face. This is followed by removal of the internal limiting membrane (ILM), stained by Indocyanine green. While pneumoretinopexy used to be employed earlier, a preoperative...

Read More

High Systolic Blood Pressure is Related to Macular Edema in Diabetic Patients

Advantages: Systolic blood pressure control might reduce macular edema in diabetic patients. Methods: Medical records of 378 patients who were hospitalized in Asan Medical Center from November 1st, 2007 to June 1st, 2011 were reviewed retrospectively. All the patients were diagnosed as non-proliferative diabetic retinopathy and were tested with Stratus optical coherence tomography (OCT) for macular edema. Blood pressure which was checked...

Read More

Vitreoretinal Interface Abnormalities Associated with Diffuse DME: Diagnosis and Management

Advantages: Diabetic diffuse macular edema may be associated with multiple vitreoretinal interface abnormalities as epimacular membranes, vitreomacular traction syndrome, lamellar macular hole and full thickness macular hole. Vitrectomy combined with ILM peeling is effective in dealing with interface disorders with encouraging anatomical and functional results. Methods: Vitrectomy combined with ILM peeling was used to deal with...

Read More

Terminologic Confusion in DME

Background: Genuine confusion in the terminology of diabetic macular edema (DME) classification has existed for a long time. Only the definitions: focal versus diffuse DME and clinically significant macular edema (CSME) have been available since the ETDRS study. This is a far from satisfactory way to define many types of DME in the era of spectral OCT. Methods: OCT records of all DME cases in a university retina clinic were reviewed to...

Read More

Design of a Comparative Study Anti-VEGF vs Surgery for DME

We will present the study-design of our prospective randomized multi-center study that will start in autumn 2012. Anti-VEGF-therapy has developed to the standard care for diabetic macular edema.  Vitrectomy is an additional treatment option that is able to stabilize DME. The pharmacokinetic effect of a vitrectomy is an increased VEGF-clearance in the eye, but also a higher clearance of intravitreally administered drugs. Consequently,...

Read More

Multiple Therapeutical Approaches for the Same DME

Advantages: Our approaches were directed all the time to the pathogenetic causes obtaining a good functional result and reducing in this way complications and secondary effects. We present a 52 years old patient (Diabetes type I for 40 years) managed by partial PRP before first seen in February 2009 with a huge retrohyaloidal macular hemorrhage in the RE (VA < 20/200). The right eye was managed by YAG laser hyaloidotomy, 25 Ga PPV and...

Read More

Comparative Study of Vitrectomy with ILM Peeling vs Anti-VEGF in DME

Advantages: To compare anatomic and functional results of vitrectomy with internal limiting membrane (ILM) peeling and anti- VEGF (Avastin) injection for the course of diabetic macular edema. Methods: Comparative non- randomized study of 68 eyes, of patients with diabetic macular edema. 50 eyes were treated with repeated injections of anti- VEGF (Avastin), 18 eyes had undergone vitrectomy with ILM peeling. Pre- and best-achieved...

Read More

Clinical Outcomes of Intravitreal Bevacizumab Combined with Laser Photocoagulation as Primary Treatment of DME

Purpose: To know the clinical outcomes of intravitreal bevacizumab with laser photocoagulation as primary treatment in the diabetic macular edema. Methods: Patients who diagnosed with DME without vitreomacular traction and not underwent any other treatment were choosen to receive an intravitreal bevacizumab injection alone in 30 eyes and an intravitreal bevacizumab injection with laser photocoagulation in 31 eyes. We compared both groups....

Read More

Intravitreal Ranibizumab Combined with Selective Laser Coagulation of Pigment Epithelium for Cystoid DME

Advantages: Selective laser coagulation of pigment epithelium (SLCPE) is effective laser procedure for treatment diffuse and focal diabetic macular edema with minimal damage of retina, but cystoid macular edema (CDME) is very torpid to different treatment modalities, and the majority of authors prefer grid laser for its treatment. We suggested that previous intravitreal ranibizumab (0.5 mg) will create conditions for effective SLCPE in...

Read More

Determination of Ischemic Diabetic Maculopathy According to SOCT Data

Advantages: To develop the coefficient of ischemia in order to characterize pathological changes of retinal architectonics in microvascular occlusion in ischemic diabetic maculopathy according to non invasive method spectral optical coherence tomography in comparison to non ischemic retina without usage of fluorescent angiography. Methods: There were 25 eyes (18 patients) with diabetic macular ischemia to which along with general clinical...

Read More

Correlation Between Subfoveal Chroidal Thickness and Stage of Diabetic Retinopathy

Correlation Between Subfoveal Chroidal Thickness and Stage of Diabetic Retinopathy Jee Taek Kim Advantages: This study demonstrates differences in choroidal thickness according to DMR stage and DME type. Methods: Medical records of patients who were diagnosed with diabetic retinopathy between March and October 2011 were reviewed, retrospectively. Choroidal thickness was measured using enhanced-depth imaging optical coherence...

Read More

Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients with Diabetic Retinopathy

Background: Diabetic retinopathy (DR) is a highly specific vascular complication of type 1 and type 2 diabetes mellitus. Calcium dobesilate (CD) or Doxium has been tested in the treatment of diabetic retinopathy showing a slowdown of the progression of the disease after long-term oral treatment, as a potent antioxidant. Endothelin-1 (ET-1) besides being a very potent vasoconstrictor, acts as a mitogen on the vascular smooth muscle and...

Read More

Can Serous Macular Detachment Help to Predict the Types of Maculopathy and the Severity of Retinopathy in Diabetic Patients?

Advantages: To search the importance of serous macular detachment (SMD) to predict the types of maculopathy and the severity of retinopathy in diabetic patients. Methods: 189 patients with retinopathy and clinically significant macular edema were included. Patients were grouped as SMD + (group I, n: 107) and SMD – (group II, n: 82) in optical coherence tomography (OCT). Fundus fluorescein angiographic (FA) findings were evaluated...

Read More

Assessment of Angiographic Findings of Diabetic Patients Who Underwent PPV for ERM or Taut Posterior Hyaloid

Advantages: To analyse the angiographic findings of diabetic patients who underwent pars plana vitrectomy for epimacular membrane or taut posterior hyaloid (TPH). Methods: Patients were grouped according to the presence of taut posterior hyaloid or ERM. Preoperative and postoperative angiographic, optical coherence tomography and visual acuity findings were compared in between groups. Arm to retinal circulation, arteriovenous transit...

Read More

PPV for Treatment of Diffuse Non Tractional DME

Purpose: To evaluate the anatomical and functional results of Pars Plana Vitrectomy (PPV), Intravitreal Triamcinolone (IVT) with or without Internal Limiting Membrane (ILM) peeling in the treatment of diffuse non tractional Diabetic Macular Edema (DME). Methods: A total of 11 eyes (9 patients), those underwent primary vitrectomy with or without ILM peeling, during the past 2 years, were included in this study. Best Corrected Visual...

Read More

Intravitreal Bevacizumab Injection Alone or Combined with Triamcinolone vs Macular Photocoagulation as Primary Treatment of DME

Purpose: To report the efficacy of a single intravitreal bevacizumab injection alone or in combination with intravitreal triamcinolone acetonide versus macular laser photocoagulation as primary treatment of diabetic macular edema. Methods:   72 eyes of 40 patients with clinically significant DME and no previous treatment were enrolled. The eyes were randomly assigned to one of three study arms: the intravitreal bevacizumab (IVB) group,...

Read More

Combined Cataract Surgery and Intravitreal Ranibizumab in Preventing Postoperative ME in Non-proliferative Diabetic Retinopathy

Purpose: To evaluate the role of intravitreal ranibizumab, injected at the time of cataract surgery on the progression of postoperative diabetic macula edema (PME) in non-proliferative diabetic retinopathy (NPDR). Setting: Multi-center, prospective randomized study. Methods: 80 Patients with NPDR and cataract were randomized to 40 only cataract surgery (Sham group) or 40-cataract surgery plus intraoperative ranibizumab injection...

Read More

Enhanced Depth Imaging OCT of the Choroid in DME

Enhanced Depth Imaging OCT of the Choroid in DME Francisco J. Ascaso Advantages: The choroidal thickness in patients with diabetic macular edema (DME) compared with that in healthy controls let us know the true role of choroids in DME. Methods: Twelve eyes of 9 patients with DME (65.5 ±8.4 years), 9 contralateral eyes without DME (60.2 ±13.7 years), and 186 eyes of 96 age-matched healthy volunteers (62.1 ±19.4 years) underwent enhanced...

Read More

The Dependence of Post-operative Visual Acuity on the Pre-operative State of Patients Operated for Complicated Diabetic Retinopathy

M. Zavorkova, L. Prochazkova, T. Benda (Usti nad Labem, Czech Republic) Advantages: Pars plana vitrectomy (PPV) helped us to resolve complications of diabetic retinopathy (DR) including tractional retinal detachment. Methods: Authors report the results of surgical interventions, performed between 2004-2009 to handle various complications of DR at the Department of Ophthalmology, Masaryk Hospital in Ústi nad Labem. PPV was performed in 106...

Read More

Congress – Optical Coherence Tomography as a Screening Method for Diabetic Macular Edema

SYMPOSIUM:MACULOPATHIES Moderator: Ferenc Kuhn Monday, June 20, 2005 Optical coherence tomography (OCT) as a screening method for diabetic macular edema Author: M. Sydorova, R. Skripnik Abstract Purpose: This study aimed to reveal early macular thickening using optical coherence tomography (OCT) measurements in diabetic patients. Methods: We investigated 15 eyes from 8 patients with diabetes but no ophthalmoscopic evidence of...

Read More

Surgical Removal and Analysis of Subfoveal Hard Exudate in Diabetic Retinopathy

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Oh Kwon, Yongsung You (Seoul, South Korea) Purpose: To study the effect of surgical removal and the lipid composition of subfoveal hard exudates in diabetic retinopathy. Material and Methods: Retrospective study was done in consecutive 7 case series with dense subfoveal large hard exudates (> 1 DA) in diabetic retinopathy, which were surgically...

Read More

Vitrectomy for Tractional Diabetic Macular Edema

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Hassan Mortada (Cairo, Egypt) Advantages: PPV, with or without ILM peeling relieves traction at the vitreoretinal interface, improves trans-vitreal oxygenation of the retina and removes growth factor reservoir in the premacular hyaloid. Methods: 46 eyes with tractional diffuse diabetic macular edema underwent PPV: 12 eyes with taut adherent posterior...

Read More

Individualized Therapy in Diabetic Maculopathy

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Ivan Fiser, Martina Rubesova (Prague, Czech Republic) Advantages: We consider diabetic macular edema a very individual disease, which cannot be treated according to a single template. No doubt that in focal edema the direct laser coagulation of leaking MA brings the best effect. Diffuse edema is more questionable; grid laser is controversial or even...

Read More

Pars Plana Vitrectomy with Removal of Internal Limiting Membrane in the Treatment of Diffuse Non Tractional Diabetic Macular Edema

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Jean-Paul Berrod, P. Genin Perriguey (Nancy, France) Advantages: Photocoagulation is currently the most recommended therapy however, the prognosis after laser treatment for diffuse edema was worse than focal edema. Pars plana vitrectomy with ILM peeling appears to be beneficial in eyes with diffuse non-tractional diabetic macular edema, and its...

Read More

Fundus Autofluorescence in Diabetic Macular Edema: Subthreshold Micropulse Diode Laser vs Modified Early Treatment Diabetic Retinopathy Study Laser Photocoagulation

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Evangelia Papavasileiou, S. Sivaprasad, S. Liazos, R. Mathew, I. Bisbas (London, UK) Advantages: The advantages of this study were to evaluate and compare fundus autofluorescence (FAF) after subthreshold micropulse diode laser versus modified Early Treatment Diabetic Retinopathy Study photocoagulation for clinically significant diabetic macular...

Read More

Focal Laser Treatment for Diabetic Macular Edema Using a Retinal Navigated Laser (NAVILAS)

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Marcus Kernt, Armin Wolf, Efstathios Vounotrypidis, Michael W. Ulbig, Anselm Kampik, Aljoscha S. Neubauer (Munich, Germany) Purpose: To investigate the applied accuracy of a navigating laser photo-coagulator when treating clinically significant macular edema. The NAVILAS® is featured with retinal movement tracking and a precise visualization of targeted...

Read More

Intravitreal Injections of Triamcinolone vs Bevacizumab vs Sham Treatment during Phacoemulsification on Diabetic Macular Edema

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Siamak Moradian, Amir Faramarz, Qiumars Heidari, Masoud Salehipoor, Mohammad Mohammadzadeh (Tehran, Iran) Advantages: To compare the results of IVT vs IVB vs sham injections at the end of phacoemulsification (PE) on diabetic macular edema (DME). Methods: In a RCT 88 diabetic patients with at least moderate NPDR were undergone one of the 3 injections, IVT...

Read More

Intravitreal Anti-VEGF Therapy (Bevacizumab) in Diabetic Macular Edema

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Veronika Aslanova, Nikolai Umanets (Odessa, Ukraine) Advantages: Intravitreal bevacizumab injection lead to a significant visual improvement in patients with diabetic macular edema soon after procedure. Methods: 28 patients (36 eyes), (24 females, 4 males), mean age 62 y/o, with diabetic macular edema were consecutively enrolled in the noncomparative...

Read More

The Short Term Efficacy of Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema

Kyu Seo Kim, Dong Hyun Jee, Sang Hee Doh, Jae Hyung Park (Suwon, South Korea) Advantages: To evaluate the short-term effect of an intravitreal injection of ranibizumab in the treatment of diabetic macular edema. Methods: We retrospectively evaluated 18 eyes of 18 patients who underwent intravitreal ranibizumab injection for the treatment of diabetic macular edema between March 1 and November 30, 2009. Complete ophthalmic examinations...

Read More

Comparison of Intravitreal Triamcinolone and Combined Triamcinolone-Bevacizumab Injection as Adjunctive Treatment to Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema

Osman Çekiç, M. Selim Kocabora, Nilay Kandemir (Istanbul, Turkey) Advantages: To assess the effectiveness of intravitreal triamcinolone and combined triamcinolone-bevacizumab injection as adjunctive treatment to grid laser for diffuse diabetic macular edema. Methods: Sixty-nine eyes of 69 patients (29 male, 40 female) with diffuse diabetic macular edema were intravitreally injected either with 4mg/0.1ml triamcinolone (n = 29) or...

Read More

The Combination of Intravitreal Bevacizumab and Phacoemulsification Surgery in Patients with Cataract and Coexisting Diabetic Macular Edema

Ozgür Bilen, Kubilhan Elmas, Ali Altýnsoy (Ankara, Turkey) Purpose: The aim of this study was to assess the efficacy of phacoemulsification combined with intravitreal bevacizumab injection in diabetics with clinically significant macular edema (CSME) and cataract. Methods: This retrospective study included diabetic patients with cataract and CSME who underwent phacoemulsification and intraocular lens implantation with a 1,25-mg...

Read More

Vitrectomy with ILM Peeling in Persistent Diabetic Macular Edema

http://www.evrs.eu/medias/2010/videos/AshrafRadwan_VP6_768K.flv Ashraf Radwan, Ahmed Ibrahim (Jeddah, Saudi Arabia) Advantages: Vitrectomy with internal limiting membrane peeling edema help in improvement of persistent diabetic macular and improvement of visual acuity. Methods: Pars plana vitrectomy (20 Gauge) with removal of posterior hyaloid then injection of Brilliant Peel dye then ILM peeling. Effectiveness / Safety: Vitrectomy with...

Read More

What about DME? We Choose a Different Way Combined Medical Approach

Authors: José Juan Escobar Barranco, Begoña Pina Marín, Barcelona, Spain Advantages: The main cause of blindness in type II diabetic patients is macular edema. We suggest a combined medical approach from the beginning of diabetic multifocal macular edema, which yields a visual acuity (VA) gain and a stabilization of the symptomatology with a good profile of safety. Methods: We show 31 eyes of 18 diabetic II patients with very poor...

Read More

Advantages of Optical Coherence Tomography and Fluorescein Angiography in Early Diagnosis of Mild Diabetic Macular Edema

Ceklic Lala (University Eye Clinic Kasindo, Eastern Sarajevo, Bosnia and Herzegovina), Latinovic Slobodanka (University Eye Clinic of Novi Sad, Novi Sad, Vojvodina-Serbia) Advantages: Comparison of two main diagnostic tools optical coherence tomography and fluorescein angiography in early detection of diabetic macular edema. Methods: We have evaluated 74 eyes of 74 diabetic patients with early changes of diabetic macular edema with both...

Read More

Vitectomy and Removal of the Internal Limiting Membrance in the Treatment of Diabetic Macular Edema

Jan Kalvoda, Bohdana Kalvodová (Department of Ophthalmology, Charles University, Prague, Czech Republic), Jaroslava Dušková (Institut of Pathology, Charles University, Prague, Czech Republic) Advantages: To evaluate the efficiency of vitrectomy with peeling of the internal limiting membrane (ILM) in eyes with chronic diffuse and/or cystoid diabetic macular edema (DME) and to perform histopathologic and morphometric analysis of the ILM....

Read More

My Way of Treating Proliferative Simultaneous Diabetic Retinopathy and Diffuse Diabetic Macular Edema in Young Patients: Triple Therapy

Pina Marin Begoña, Escobar Barranco José Juan, Fernández Bonet Manel Advantages: Sequenced triple therapy with anti Vascular Endothelial Growth Factor (antiVEGF) followed by complete photocoagulation and intravitreal triamcinolone allows treating diffuse diabetic macular edema, the most important factor regarding final visual acuity, without neglecting the treatment of neovascularization, the primary responsible of ocular integrity;...

Read More

Intravitreal Bevacizumab Versus Intravitreal Triamcinolone For Diabetic Macular Edema With Severe Hard Exudates

Ben Yahia S, Jenzeri S, Hmidi K, Attia S, Zaouali S, Khairallah M Purpose: To compare response after intravitreal bevacizumab (IVB) or triamcinolone (IVT) in diabetic macular edema with severe hard exudates. Methods: Forty-eight eyes were randomly assigned to either IVB or IVT. Follow-up was > 6 months. Results: There was significant improvement in BCVA in the IVT group when compared with the IVB group (P= .04). Complete resolution of...

Read More

Effects of Bevacizumab on Diabetic Macular Edema in Proliferative Diabetic Retinopathy

http://www.evrs.eu/medias/2008/congress/Effects-of-Bevacizumab-on-Diabetic-Macular-Edema-in-Proliferative-Diabetic-Retinopathy.flv Lala Ceklic (University Eye Clinic Kasindo, Eastern Sarajevo, Bosnia and Herzegovina), Slobodanka Latinovic (University Eye Clinic of Novi Sad, Novi Sad, Vojvodina-Serbia) Advantages: The non-selective anti vascular endothelial growth factor antibody (VEGF) bevacizumab (Avastin) has been used for the treatment...

Read More

Intravitreal Injection of Triamcinolone for the Treatment of Diabetic Macular Edema

Ashraf Shoukry, (Doha Qatar, Saudi Arabia), Walid A. Alturki, MD (Jeddah, Saudi Arabia) PURPOSE: Can 4mg intravitreal triamcinalone acetonide effectively treat diabetic macular edema that is refractory to conventional laser treatment? METHODS: 50 eyes were enrolled in the study. Preinjection best corrected visual acuity; intraocular pressure and optical coherence tomography were done for each patient. Intraocular injection of 4 mg of...

Read More

An OCT Stepped Approach to Diabetic Macular Oedema

Pietro Rossi, MD (Genoa, Italy), Carlandrea Trillo, (Genova, Italy) PURPOSE: To evaluate the time and results of intravitreal steroids and ILM peeling in the management of diffuse diabetic macula oedema. METHODS: Comparative, interventional open label study. Primary endpoint: reduction in retinal thickness. Secondary endpoint: changes in visual acuity. 25 patients with diabetic diffuse macular oedema were randomly assigned to argon laser...

Read More

Diabetic Macular Edema Before and After Intravitreal Triamcinolone Injection

Alireza Ramezani, (Tehran, Iran), Homa Tabatabaei, MD (Tehran, Iran), Hamid Ahmadieh, MD (Tehran, Iran) PURPOSE: The therapeutic effect of intravitreal triamcinolone (IVT) on diabetic macular edema (DME), which is a chronic disease, has been shown to be temporary. This study was conducted to compare IVT treatment effect with the natural course of refractory DME in a particular group of the eyes. We chose one group for both interventions to...

Read More

Response of Different Patterns of Diabetic Macular Edema to Treatment with a Sustained-release Dexamethasone Posterior-segment Drugdelivery System

Baruch D. Kuppermann, MD, PhD (Irvine, CA),* Connie Chou, PhD (Irvine, CA),* David V. Weinberg, MD (Milwaukee, WI),* Scott M. Whitcup, MD (Irvine, CA),* Julia A. Haller, MD (Baltimore, MD),* Mark S. Blumenkranz, MD (Stanford, CA),* George A. Williams, MD (Royal Oak, MI)* PURPOSE: To evaluate the response of different patterns of persistent diabetic macular edema (DME) unresponsive to prior medical or laser therapy to treatment with a novel...

Read More

Ultrastructural Morphometry of the Internal Limiting Membrane (ILM) in the Laboratory Universal Computer Image Analysis System

Bohdana Kalvodova, MD (Prague, Czech Republic), Jaroslava Duskova, MD, PhD (Prague, Czech Republic), Tarek Aboutable, MD, PhD (Prague, Czech Republic), Martin Janek, MD (Prague, Czech Republic), Evantia Omoscharkas, MD (Prague, Czech Republic) PURPOSE: Removal of the posterior hyaloid and ILM during microsurgery appears to have a positive influence on the resolution of diabetic macular edema (DME) and idiopathic macular hole (IMH)....

Read More

Objective Quantification of Disappearance of Plaque-like Hard Exudates in Diabetic Macular Edema after Intravitreal Triamcinolone Injection

Osman Cekic, MD, PhD (Isparta, Turkey), Yavuz Bardak, MD (Isparta, Turkey), Uzeyir Y ´ yld´ yzoglu, MD (Isparta, Turkey), Sahin Ufuk T ´ yg, MD (Isparta, Turkey) PURPOSE: To quantify the disappearance of plaque-like hard exudates after 4 mg intravitreal triamcinolone acetonide injection in eyes with diabetic macular edema. METHODS: This retrospective interventional case series included 22 eyes of 14 patients with chronic diabetic macular...

Read More

Alterations in Ocular Perfusion after Intravitreal Triamcinolone Injection for Diabetic Macular Edema

Osman Cekic, MD, PhD (Isparta, Turkey), Yavuz Bardak (Isparta, Turkey), Aykut Demirkol, MD (Isparta, Turkey), Ahmet Yepildao, MD (Isparta, Turkey), Mustafa Yalç ´ yn, MD (Isparta, Turkey), Orhan Oyar, MD (Isparta, Turkey) PURPOSE: To investigate ocular hemodynamic changes after intravitreal triamcinolone acetonide injection in patients with diabetic macular edema. METHODS: Prospective interventional case-control study. Thirteen eyes of 13...

Read More

Effects of Triamcinolone Injection on Macular Functions In Diabetic Macular Edema

Yavuz Bardak, MD (Isparta, Turkey), Osman Cekic, MD, PhD (Isparta, Turkey), Ufuk Sahin Tig, MD (Isparta, Turkey), Aykut Arslan Yildiz, MD (Isparta, Turkey) PURPOSE: To investigate effects of intravitreal triamcinolone injection on macular functions in patients with diabetic macular edema. METHODS: Intravitreal triamcinolone (4mg) injection was applied to 18 eyes of 18 subjects (Type II Diabetus Mellitus, mean age 57, M/F:9/9) with diabetic...

Read More

Intravitreal Triamcinolone in the Treatment of Diabetic Maculopathy

Leyla S. Atmaca, MD (Ankara, Turkey), Elif Akmese, MD (Ankara, Turkey), Selcen Celik, MD (Ankara, Turkey) PURPOSE: To evaluate the efficacy of the intravitreal triamcinolone acetonide injection in the treatment of diabetic maculopathy. METHODS: This prospective, non-randomized, uncontrolled study included patients with diabetic maculopathy who were treated with 4 mg (0.1 ml) of triamcinolone acetonide intravitreally. Full ophthalmic...

Read More

Vitrectomy for Diabetic Macular Edema: Study Design and Preliminary Results of VIDE Study, an Italian Clinical Trial

http://www.evrs.eu/medias/2006/congress/Vitrectomy-for-Diabetic-Macular-Edema:-Study-Design-and-Preliminary-Results-of-VIDE-Study,-an-Italian-Clinical-Trial.swf Barbara Parolini, MD (Verona, Italy), Giacomo Panozzo, MD (Verona, Italy), Fabio Patelli, MD (Milan, Italy) PURPOSE: This is a three-centers prospective clinical trial on diffuse, non-tractional diabetic macular edema comparing the effects of simple vitrectomy (core PPV with PVD...

Read More

Posterior Juxtascleral Injection of Triamcinolone Acetonide for Cases of Diabetic Macular Edema Unresponsive or Unamenable to Laser Treatment

http://www.evrs.eu/medias/2006/congress/Posterior-Juxtascleral-Injection-of-Triamcinolone-Acetonide-for-Cases-of-Diabetic-Macular-Edema-Unresponsive-or-Unamenable-to-Laser-Treatment.swf Franco M. Recchia, MD (Nashville, TN), Jaclyn Lekse Kovach, MD (Nashville, TN), Guri Bronner, MD (Nashville, TN), Srilakshmi Maguluri, MD (Nashville, TN) PURPOSE: The risks of endophthalmitis, retinal detachment, and glaucoma associated with intravitreal...

Read More

Primary Intravitreal Bevacizumab (Avastin) for the Treatment of Diabetic Macular Edema: Results of the Pan-American Collaborative Retina Study Group

http://www.evrs.eu/medias/2006/congress/Primary Intravitreal Bevacizumab (Avastin) for the Treatment of Diabetic-Macular-Edema:-Results-of-the-Pan-American-Collaborative-Retina-Study-Group.swf http://www.evrs.eu/medias/2006/congress/Primary%20Intravitreal%20Bevacizumab%20(Avastin)%20for%20the%20Treatment%20of%20Diabetic-Macular-Edema:-Results-of-the-Pan-American-Collaborative-Retina-Study-Group.flv J. Fernando Arevalo, MD, FACS (Caracas,...

Read More

Interim Results of the R.E.A.D. Study: Ranibizumab for Edema of the Macula in Diabetes

http://www.evrs.eu/medias/2006/congress/Interim-Results-of-the-R.E.A.D.-Study:-Ranibizumab-for-Edema-of-the-Macula-in-Diabetes.swf Diana V. Do, MD (Baltimore, MD), Quan Dong Nguyen, MD (Baltimore, MD),* Sinan Tatlipinar, MD (Denizli, Turkey), Syed Mahmood Shah, MBBS (Baltimore, MD), Pamela Singletary, COT (Baltimore, MD), Julia A. Haller, MD (Baltimore, MD),* Edward J. Quinlan, MD (Baltimore, MD), Jennifer U. Sung, MD (Baltimore, MD),...

Read More

Intravitreal Injection Versus Systemic Bevacizumab (Avastin) Therapy for Diabetic Macular Edema

http://www.evrs.eu/medias/2006/congress/Intravitreal-Injection-Versus-Systemic-Bevacizumab-(Avastin)-Therapy-for-Diabetic-Macular-Edema.swf Murat Oncel, MD (Istanbul, Turkey) PURPOSE: To compare the safety and efficacy of intravitreal and systemic bevacuzimab(Avastin) in the treatment of patients with clinically significant diabetic macular edema(DME). METHODS: 23 patients with clinically significant DME involving the foveal center were...

Read More

Optical Coherence Tomography Following Pegaptanib Therapy in Diabetics: A Bioanatomic Study of DME

http://www.evrs.eu/medias/2006/congress/Optical-Coherence-Tomography-Following-Pegaptanib-Therapy-in-Diabetics:-A-Bioanatomic-Study-of-DME.swf Mauro Goldbaum, MD (New York, NY),* David R. Guyer, MD (New York, NY),* Barrett Katz,MD (New York, NY)* PURPOSE: Preclincal and clinical data support a role for vascular endothelial growth factor (VEGF)165 in the pathogenesis of ocular neovascular diseases, suggesting that inhibiting the effects of...

Read More

Pegaptanib Sodium in Diabetic Retinopathy: Improvements in Diabetic Macular Edema, Retinal Neovascularization, and Severity of Diabetic Retinopathy

http://www.evrs.eu/medias/2006/congress/Pegaptanib-Sodium-in-Diabetic-Retinopathy:-Improvements-in-Diabetic-Macular-Edema,-Retinal-Neovascularization,-and-Severity-of-Diabetic-Retinopathy.swf Victor Hugo Gonzalez, MD (Mcallen, TX) PURPOSE: Preclinical data indicate that pegaptanib, an aptamer targeting VEGF165, can reverse diabetesinduced blood-retinal barrier breakdown; clinical trials demonstrate pegaptanib’s efficacy in treating...

Read More

Predictive Factors for Visual Outcome after Intravitreal Triamcinolone Acetonide Injection for Diabetic Macular Edema

Rishi P. Singh, MD (Shaker Heights, OH), Oswaldo FM Brasil, MD (Cleveland, OH), Anat Galor, MD (Cleveland, Ohio), Scott D Smith, MD, MPH (Cleveland, OH), Careen Y. Lowder, MD (Cleveland, OH), Jonathan E. Sears, MD (Cleveland, OH), Peter K. Kaiser, MD (Cleveland, OH) PURPOSE: To evaluate the predictive factors for visual outcome after intravitreal triamcinolone acetonide injection in the treatment of diabetic macular...

Read More

The Effect of an Epiretinal Membrane on Intravitreal Triamcinolone Treatment for Diabetic Macular Edema

http://www.evrs.eu/medias/2006/congress/The-Effect-of-an-Epiretinal-Membrane-on-Intravitreal-Triamcinolone-Treatment-for-Diabetic-Macular-Edema.swf Parin S. Gohel, MD (Denver, CO), Gian Paolo Giuliari, MD (Caracas, Venezuela), Antonio P. Ciardella, MD (Denver, CO) PURPOSE: To evaluate the efficacy of intravitreal triamcinolone injection (IVTA) for the treatment of diabetic macular edema (DME) in eyes with an epiretinal membrane (ERM)...

Read More

The Effect of the Oral PKC ß Inhibitor Ruboxistaurin on Visual Loss and Diabetic Macular Edema (DME)

http://www.evrs.eu/medias/2006/congress/The-Effect-of-the-Oral-PKC-B-Inhibitor-Ruboxistaurin-on-Visual-Loss-and-Diabetic-Macular-Edema-(DME).swf Ronald P. Danis, MD (Madison, WI),* Aniz Girach, MD (Erl Wood, UK),* Lloyd P. Aiello, MD PhD (Boston, MA),* Matthew D. Davis, MD (Madison, WI),* Roy C. Milton, PhD (Baltimore, MD),* Matthew J. Sheetz, MD, PhD (Indianapolis, IN),* Toni E Lin, MD (Indianapolis, IN),* Xin Zhi, PhD (Indianapolis, IN),*...

Read More

VEGF Small Interfering (si) RNA, Cand5, for Treatment of Diabetic Macular Edema (DME)

http://www.evrs.eu/medias/2006/congress/VEGF-Small-Interfering-(si)-RNA,-Cand5,-for-Treatment-of-Diabetic-Macular-Edema-(DME).swf Jonathan L. Prenner, MD (New Brunswick, NJ),* R.A.C.E.TM Study Group PURPOSE: To report the clinical outcomes of patients from the R.A.C.E. (RNAi Assessment for Cand5 in patients with DME) study, in which Cand5, an anti-VEGF siRNA, was evaluated for the treatment of DME. METHODS: The R.A.C.E.TM study is a Phase...

Read More

Subthreshold Micropulse Diode Laser Photocoagulation in the Treatment of Diabetic Clinically Significant Macular Edema

http://www.evrs.eu/medias/2006/congress/Subthreshold-Micropulse-Diode-Laser-Photocoagulation-in-the-Treatment-of-Diabetic-Clinically-Significant-Macular-Edema.swf Neelakshi Bhagat, MD (Newark, NJ), Ruben Grigorian, MD (Newark, NJ), Nilang Patel, MD (Newark, NJ), Marco A. Zarbin, MD, PhD (Newark, NJ), Monique Roy, MD (Newark, NJ), Arthur Tutela, MD (Newark, NJ) PURPOSE: To evaluate the efficacy of Subthreshold Micropulse Diode Laser...

Read More

Diurnal Variation in Retinal Thickening Measured By OCT

http://www.evrs.eu/medias/2006/congress/Diurnal-Variation-in-Retinal-Thickening-Measured-By-OCT.swf Michel J. Shami, MD (Lubbock, TX), Ronald P. Danis, MD (Madison, WI), Diabetic Retinopathy Clinical Research Network PURPOSE: To evaluate diurnal variation in Optical Coherence Tomography (OCT) measured retinal thickness in patients with center-involved diabetic macular edema (DME). METHODS: Ninety-six subjects with DME were recruited at 25...

Read More

Clinical Detection of Diabetic Macular Edema (DME) Using the Automated Retinal Imaging System

Antonio P. Ciardella, MD (Denver, CO) PURPOSE: To compare stereo photographic images produced by the Automated Retinal Imaging System (ARIS) and the retinal image maps created using Optical Coherence Tomography (Stratus OCT-III) and to determine if the ARIS is an effective screening tool to detect DME. We hypothesized that the ARIS photos will be an effective, noninvasive screening tool to detect macular edema in diabetic...

Read More

The Use of Microperimetry Analysis to Reduce the Risk of Laser-induced Damage to Visual Functioning in Patients with CSME and Extra-foveal Fixation

Fareed Ali, MD, FRCS(C) (Toronto, Canada), Narendra Armogan, MD, FRCS(C) (Mississauga, Canada), Vivian Yin, BA (Toronto, Canada), Tammy Hummel, CCRC (Mississauga, Canada) PURPOSE: To evaluate the efficacy of microperimetry analysis, which provides correlation of sensitivity data points with specific points on the retina, in detecting areas of the retina that may need to be avoided during laser treatment of diabetic clinically significant...

Read More

The Natural History of DME: Literature Review and Personal Experience

http://www.evrs.eu/medias/2005/congress/The-Natural-History-of-DME:-Literature-Review-and-Personal-Experience.swf Barbara Parolini – for the Vide Study Group Purpose: To better understand the natural history of diabetic macular edema (DME). Methods: Literature review and personal experience on more than 40 patients followed for six months or more without any therapeutic intervention. Results: DME may show stability or even improvement of...

Read More

The Effect of Intravitreal Triamcinolone Acetonide on Optic Nerve Head Topography

Yusuf Akar, Cemil Apaydin, Meryem Altin, Asli Oner Purpose: To assess the effects of intravitreal triamcinolone acetonide injection on optic nerve head topography. Methods: The study population consisted of one eye of 23 patients with type 2 diabetes mellitus with clinically significant macular edema. None of the patients had proliferative diabetic retinopathy or a history of retinal laser photocoagulation. All eyes had received 4 mg of...

Read More

The Many Faces of Triamcinolone

Giampaolo Gini Purpose: To present the indications and the limits of triamcinolone in the treatment of macular conditions both as single treatment by itself, as a preparatory step for further procedures or an intraoperatory instrument. Methods: In dealing with macular edema understanding the causes determining the condition is essential in choosing a successful therapeutic strategy. Thus, triamcinolone finds different indications according...

Read More

Serous Macular Detachment in Diabetic Cystoid Macular Edema

http://www.evrs.eu/medias/2005/congress/Serous-Macular-Detachment-in-Diabetic-Cystoid-Macular-Edema.swf Murat Karacorlu, MD, Hakan Ozdemir, MD, Serra Karacorlu, MD, Fevzi Senturk, MD – Istanbul Retina Institute, Istanbul, Turkey Purpose: To define serous macular detachment (SMD) in patients with diabetic cystoid macular edema (CME). Methods: This study involved 78 eyes of 58 patients with diabetic CME. The patients underwent complete...

Read More

Optical Coherence Tomography (OCT) as a Screening Method for Diabetic Macular Edema

http://www.evrs.eu/medias/2005/congress/Optical-Coherence-Tomography-(OCT)-as-a-Screening-Method-for-Diabetic-Macular-Edema.swf M. Sydorova, R. Skripnik Purpose: This study aimed to reveal early macular thickening using optical coherence tomography (OCT) measurements in diabetic patients. Methods: We investigated 15 eyes from 8 patients with diabetes but no ophthalmoscopic evidence of retinopathy, 20 eyes from 10 patients with...

Read More
content top